{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:30Z","timestamp":1791357390727,"version":"4.3.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.drugalcdep.2013.02.035","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T23:01:36Z","timestamp":1364338896000},"page":"427-433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): Time course and severity of withdrawal in baboons"],"prefix":"10.1016","volume":"132","author":[{"given":"Amy K.","family":"Goodwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise M.","family":"Weerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0005","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/dta.254","article-title":"An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results","volume":"3","author":"Andresen","year":"2011","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0010","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s00213-005-0003-x","article-title":"Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) and its metabolic precursor, gamma-butyrolactone (GBL) in rats","volume":"181","author":"Baker","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0015","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/02791072.2007.10399870","article-title":"Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study","volume":"39","author":"Barker","year":"2007","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.brainresprot.2005.04.001","article-title":"Withdrawal syndrome from gamma-hydroxybutyric acid (GHB) and 1,4-butanediol (1,4-BD) in Sardinian alcohol-preferring rats","volume":"15","author":"Carai","year":"2005","journal-title":"Brain Res. Brain Res. Protoc."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1254\/jphs.FP0071487","article-title":"Gamma-aminobutyric acidB (GABAB)-receptor mediation of different in vivo effects of gamma-butyrolactone","volume":"106","author":"Carai","year":"2008","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/jpet.102.047860","article-title":"The role of GABA-B receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studies","volume":"305","author":"Carter","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.04.012","article-title":"Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse","volume":"104","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0040","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.pbb.2004.01.009","article-title":"Comparison of the actions of gamma-butyrolactone and 1,4-butanediol in Swiss-Webster mice","volume":"77","author":"de Fiebre","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0045","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000333022","article-title":"Gamma-hydroxybutyrate detoxification by titration and tapering","volume":"18","author":"de Jong","year":"2012","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0050","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jat\/25.7.576","article-title":"Application of a convenient extraction procedure to analyze gamma-hydroxybutyric acid in fatalities involving gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol","volume":"25","author":"Duer","year":"2001","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0055","series-title":"GHB and its Precursor GBL: An Emerging Trend Case Study","author":"European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)","year":"2008"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0060","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0741-8329(99)00090-7","article-title":"Abuse and therapeutic potential of gamma-hydroxybutyric acid","volume":"20","author":"Galloway","year":"2000","journal-title":"Alcohol"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/bms.1200190207","article-title":"Stable isotope dilution analysis of 4-hydroxybutyric acid: an accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria","volume":"19","author":"Gibson","year":"1990","journal-title":"Biomed. Environ. Mass. Spectrom."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0070","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00213-005-2165-y","article-title":"Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons","volume":"180","author":"Goodwin","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00213-006-0534-9","article-title":"Chronic intragastric administration of gamma-butyrolactone (GBL) produces physical dependence in baboons","volume":"189","author":"Goodwin","year":"2006","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-009-1477-8","article-title":"Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons","volume":"204","author":"Goodwin","year":"2009","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0085","first-page":"217","article-title":"Intravenous self-administration of gamma-hydroxybutyrate (GHB) in baboons","volume":"114","author":"Goodwin","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0090","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00213-012-2851-5","article-title":"Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons","volume":"225","author":"Goodwin","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0095","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3109\/10826080903443628","article-title":"Legal highs on the internet","volume":"45","author":"Hillebrand","year":"2010","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0100","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/qjmed\/hcq066","article-title":"Legal \u2018highs\u2019 available through the Internet-implications and solutions?","volume":"103","author":"Jones","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0105","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.fbp.0000082131.08343.0e","article-title":"Physical dependence in baboons chronically treated with low and high doses of diazepam","volume":"14","author":"Kaminski","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/dta.210","article-title":"GHB and synthetic cathinones: clinical effects and potential consequences","volume":"3","author":"Karila","year":"2010","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00213-007-0718-y","article-title":"Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348","volume":"192","author":"Koek","year":"2007","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0120","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1124\/jpet.109.151845","article-title":"Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348)","volume":"330","author":"Koek","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0125","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0091-3057(82)90366-5","article-title":"A tethering system for intravenous and intragastric drug administration in the baboon","volume":"17","author":"Lukas","year":"1982","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.drugalcdep.2004.01.012","article-title":"Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review","volume":"75","author":"McDonough","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0014-2999(03)01486-9","article-title":"Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys","volume":"466","author":"McMahon","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/105504901750532111","article-title":"Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal","volume":"10","author":"Miotto","year":"2001","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0145","series-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council","year":"2011"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0376-8716(00)00191-5","article-title":"GHB: a new and novel drug of abuse","volume":"63","author":"Nicholson","year":"2001","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00139709-200423010-00003","article-title":"Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate","volume":"23","author":"Palmer","year":"2004","journal-title":"Toxicol. Rev."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0160","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1196\/annals.1369.055","article-title":"Evaluation for the withdrawal syndrome from gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines","volume":"1074","author":"Quang","year":"2006","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0165","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1081\/ADA-120020529","article-title":"Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management","volume":"29","author":"Rosenberg","year":"2003","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0006-2952(65)90073-0","article-title":"Preliminary report on the metabolism of g-butyrolactone and g-hydroxybutyric acid","volume":"14","author":"Roth","year":"1965","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0175","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0006-2952(68)90010-5","article-title":"Evidence that central nervous system depression by 1,4-butanediol is mediated through a metabolite, gamma hydroxybutyrate","volume":"17","author":"Roth","year":"1968","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0180","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/15563650.2012.702218","article-title":"The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol","volume":"50","author":"Schep","year":"2012","journal-title":"Clin. Toxicol. (Phila.)"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0736-4679(01)00324-9","article-title":"A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol","volume":"21","author":"Schneir","year":"2001","journal-title":"J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0190","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1016\/0006-2952(89)90645-X","article-title":"In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes","volume":"38","author":"Snead","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0195","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1592\/phco.21.20.1486.34472","article-title":"A comprehensive review of MDMA and GHB: two common club drugs","volume":"21","author":"Teter","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0200","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/sj.clpt.6100037","article-title":"Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers","volume":"81","author":"Thai","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0205","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.fct.2012.10.009","article-title":"Comparative study of equimolar doses of gamma-hydroxybutyrate (GHB), 1,4-butanediol (1,4-BD) and gamma-butyrolactone (GBL) on catalepsy after acute and chronic administration","volume":"51","author":"Towiwat","year":"2013","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0210","first-page":"285","article-title":"Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons","volume":"9","author":"Weerts","year":"1998","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0215","first-page":"41","article-title":"Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons","volume":"285","author":"Weerts","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0220","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00213-004-2079-0","article-title":"Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons","volume":"179","author":"Weerts","year":"2005","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0225","series-title":"1,4-Butanediol (1,4-BD) Pre-review Report","author":"World Health Organization (WHO)","year":"2012"},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1017\/S1481803500010034","article-title":"Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review","volume":"10","author":"Wojtowicz","year":"2008","journal-title":"Can. J. Emerg. Med."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0235","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/dta.292","article-title":"Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD)","volume":"3","author":"Wood","year":"2011","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0240","first-page":"251","article-title":"Abuse liability of benzodiazepines","volume":"39","author":"Woods","year":"1987","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0245","first-page":"163","article-title":"Development of tolerance to and physical dependence on barbiturates in rhesus monkeys","volume":"172","author":"Yanagita","year":"1970","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drugalcdep.2013.02.035_bib0250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJM200101113440202","article-title":"Adverse events, including death associated with the use of 1,4-butanediol","volume":"344","author":"Zvosec","year":"2001","journal-title":"N. Engl. J. Med."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871613000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871613000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T12:48:55Z","timestamp":1644670135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871613000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0376871613000987"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.035","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physical dependence on gamma-hydroxybutrate (GHB) prodrug 1,4-butanediol (1,4-BD): Time course and severity of withdrawal in baboons","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}